A recent study showed that rates of antiretroviral therapy in enrollees living with HIV increased over the years, but women ...

Early antiretroviral (ARV) agents had dramatic toxic side effects; since the advent of ARV therapy (ART), treatment has evolved to become more tolerable. HIV-associated neurocognitive disorders ...

Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...

Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of ...

点击上方“感染学苑” ...

Global trends since 2005 indicate a significant decline in CD4+ count evaluations around the time of ART initiation among ...

A landmark achievement in its history came in 2003 when it became the first organisation in Tanzania to provide antiretroviral (ARV) therapy to patients. At the time, ARVs were prohibitively expensive ...

Merck MRK announced positive topline data from two pivotal phase III studies evaluating the investigational, once-daily, oral ...

HIV encephalopathy, a severe brain complication of HIV/AIDS, affects memory and cognition. Expert stresses early intervention ...

US-based pharmaceutical company MSD has reported positive results from two Phase III trials of doravirine/islatravir (DOR/ISL ...

US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...